KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Income from Continuing Operations (2017 - 2026)

Amneal Pharmaceuticals has reported Income from Continuing Operations over the past 9 years, most recently at 49573000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 339.0% year-over-year to 49573000.0; the TTM value through Dec 2025 reached 127933000.0, up 273.17%, while the annual FY2025 figure was 127933000.0, 273.17% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 49573000.0 at Amneal Pharmaceuticals, up from 18132000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 49573000.0 in Q4 2025 and troughed at 240081000.0 in Q2 2022.
  • A 5-year average of 11462300.0 and a median of 4668500.0 in 2022 define the central range for Income from Continuing Operations.
  • On a YoY basis, Income from Continuing Operations climbed as much as 1135.41% in 2023 and fell as far as 1493.73% in 2023.
  • Year by year, Income from Continuing Operations stood at 20463000.0 in 2021, then surged by 71.39% to 5855000.0 in 2022, then plummeted by 1493.73% to 93313000.0 in 2023, then surged by 77.77% to 20742000.0 in 2024, then surged by 339.0% to 49573000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for AMRX at 49573000.0 in Q4 2025, 18132000.0 in Q3 2025, and 35610000.0 in Q2 2025.